What Owkin does
Owkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical development, and (via a spin-out) diagnostics. Its core platform is K Pro, described by Owkin as an AI scientist for biopharma that orchestrates agentic AI skills to reason over multimodal patient data and biological knowledge, with scientists guiding hypotheses and decisions. Owkin also positions its MOSAIC multimodal oncology dataset and its clinical-research workflows (including a federated/secure approach to patient data access) as key differentiators for producing clinically relevant models and trial decision support.
Commercially, Owkin’s approach is largely B2B: it licenses K Pro and its associated data and AI capabilities to pharmaceutical and healthcare organizations and collaborates on programs spanning target discovery, patient subgroup identification, trial optimization (e.g., covariate adjustment / external control arms), and real-world validation. In 2026, Owkin expanded partnership announcements to include new licensing agreements (for example, Servier, Boehringer Ingelheim) and K Pro “agent building” arrangements (for example, AstraZeneca), and it continued to operationalize its agentic infrastructure through integrations and agent releases (including Pathology Explorer via Anthropic’s Claude for Healthcare and Life Sciences).